Skip to content

Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects

A Randomized, Open-label, Oral Dose, Crossover Study to Compare the Safety and Pharmacokinetics Between Co-administration and Fixed Dose Combination of DWC20155 and DWC20156 in Healthy Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02952547
Enrollment
52
Registered
2016-11-02
Start date
2016-10-30
Completion date
2017-01-10
Last updated
2017-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study to Compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects

Interventions

Sponsors

Daewoong Pharmaceutical Co. LTD.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI ≥ 18.5 and ≤ 27.0 kg/m2. * No clinically significant findings * Age 19-55 years at screening

Exclusion criteria

* Who has allergy to investigational product

Design outcomes

Primary

MeasureTime frame
Maximum Plasma Concentration (Cmax)0-24 hours
Area under the plasma concentration versus time curve (AUC)0-24 hours

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026